BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
PI Industries Ltd. offers visible growth in topline and earnings from three new units started over Q4 FY20 and H1 FY21 as per the Indian agro chemical CSM leader’s FY20 annual report.
The management has also discussed initiatives to beef up research and development capabilities
1. to increase the pace of commercialization of molecules to at least 10 every year and 2. new chemistry, including the latest in flourination process.
New product launches and Isagro Asia acquisition are added growth catalysts that will likely support healthy growth in PI Industries custom synthesis manufacturing (CSM) segment.
This is based on innovators looking to Indian companies as alternative sources for critical chemical intermediates in agrochem and other chemical segments, especially in pharma CSM, which the company sees as a new growth engine.
PI Industires is already engaged with global and India pharma companies in testing intermediates for a Covid-19 drug, the approval for which is expected in H2 FY21.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR